Novartis Q1 Core EPS Declines 15%, Missing Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NVS?
Source: seekingalpha
- Core EPS Decline: Novartis reported a 15% decline in Q1 core EPS, with a 13% drop in constant currency, reaching $1.99, which missed consensus estimates by $0.08, indicating pressure on the company's profitability.
- Net Sales Drop: The company's net sales fell 1% year-over-year and 5% in constant currency to $13.11 billion, missing consensus by $0.37 billion, highlighting challenges in market competition.
- Free Cash Flow Performance: Novartis generated $3.3 billion in free cash flow, which remains stable; however, the overall performance decline may impact future investments and shareholder returns.
- Full-Year Guidance Reaffirmed: The company reaffirmed its 2026 full-year guidance, expecting low single-digit growth in net sales and a low single-digit decline in core operating income, indicating ongoing efforts to seek growth amid patent expiration pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 145.470
Low
112.00
Averages
127.75
High
143.00
Current: 145.470
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis Q1 Earnings Announcement Scheduled
- Earnings Release Date: Novartis is set to announce its Q1 earnings on April 28 before market open, with consensus EPS estimate at $2.07 and revenue expected at $13.48 billion, indicating significant market anticipation for the company's performance.
- Historical Performance Review: Over the past two years, Novartis has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing a stable performance that bolsters investor confidence amid market scrutiny.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on Novartis's future growth.
- Market Reaction Analysis: Despite facing 'historic' patent cliffs, analysts remain optimistic about Novartis's growth potential, suggesting that the company’s innovation and market strategies could lead to sustained growth opportunities.
See More
Novartis' Rhapsido Approved by EU for Chronic Spontaneous Urticaria
- Drug Approval: Novartis' Rhapsido (remibrutinib) has received approval from the European Commission for adult patients with chronic spontaneous urticaria (CSU) who have an inadequate response to H1-antihistamine treatment, marking a significant advancement in the company's dermatological portfolio.
- Market Potential: Chronic spontaneous urticaria affects approximately 40 million people globally, with nearly twice as many women as men, highlighting Rhapsido's substantial market potential in addressing unmet medical needs.
- Clinical Trial Success: In the Phase 3 REMIX 1 & 2 studies involving 925 patients who remained symptomatic on second-generation H1-antihistamines, Rhapsido demonstrated significant superiority over placebo in itch, hives, and weekly urticaria activity at Week 12, with a favorable safety profile.
- Future Development Directions: In addition to CSU, Rhapsido is also being developed for chronic inducible urticaria, food allergies, and hidradenitis suppurativa, further expanding its market applications.
See More
Novartis CEO Warns of U.S. Drug Pricing Policy Impact
- Pricing Policy Warning: Novartis CEO Vas Narasimhan warned that the U.S. drug pricing policy under President Trump poses a 'very difficult situation' for both drugmakers and patients, with the reality expected to set in within the next 18 months, potentially impacting stock prices and market confidence.
- Innovation Incentive Reform: He emphasized that Novartis is focused on urging European and Japanese governments to quickly change how they reward innovation; failure to do so could delay the entry of novel medicines into these markets, affecting patient access and potentially diminishing the company's competitiveness globally.
- Significant Long-term Implications: Narasimhan stated that the long-term implications of the drug pricing policy will be profound, potentially stifling innovation within the pharmaceutical industry and impacting the speed of new drug development and market entry, presenting strategic challenges for the company.
- Market Reaction Expectations: As the policy's effects become more apparent, Novartis may face pressure from investors and the market, particularly regarding its performance in drug innovation and market access, which could affect its future financial performance and shareholder confidence.
See More
BYD Faces EU Scrutiny Over Labor Abuse Allegations at Hungary Factory
- Labor Abuse Allegations: BYD has become the first Chinese company scrutinized by the European Parliament over allegations of labor abuses at its Hungary factory, highlighting increasing international regulatory attention on Chinese firms operating abroad.
- Working Conditions Investigation: A report by the New York-based watchdog China Labor Watch (CLW) claims that contractors at the factory kept thousands of employees working seven days a week with shifts exceeding 12 hours, indicating significant shortcomings in labor rights protections in the region.
- Employee Interviews Findings: CLW conducted interviews with 50 workers and visited the factory three times over the past months, revealing the harsh working conditions faced by employees, which could negatively impact BYD's brand image and reputation.
- Market Reaction Potential: This incident may raise investor concerns regarding BYD's operational risks in the European market, potentially affecting its competitive position in the global electric vehicle sector, especially as labor rights gain more attention.
See More
Novartis Q1 Core EPS Declines 15%, Missing Consensus
- Core EPS Decline: Novartis reported a 15% decline in Q1 core EPS, with a 13% drop in constant currency, reaching $1.99, which missed consensus estimates by $0.08, indicating pressure on the company's profitability.
- Net Sales Drop: The company's net sales fell 1% year-over-year and 5% in constant currency to $13.11 billion, missing consensus by $0.37 billion, highlighting challenges in market competition.
- Free Cash Flow Performance: Novartis generated $3.3 billion in free cash flow, which remains stable; however, the overall performance decline may impact future investments and shareholder returns.
- Full-Year Guidance Reaffirmed: The company reaffirmed its 2026 full-year guidance, expecting low single-digit growth in net sales and a low single-digit decline in core operating income, indicating ongoing efforts to seek growth amid patent expiration pressures.
See More
European Stocks Expected to Open Higher Amid Iran Proposal and Earnings Reports
- Market Opening Expectations: European stocks are expected to open slightly higher on Tuesday, with the U.K.'s FTSE 100, Germany's DAX, France's CAC 40, and Italy's FTSE MIB all showing gains, reflecting investor optimism ahead of upcoming earnings reports.
- Earnings Reports Focus: Companies such as Novartis, Airbus, BP, and Barclays are set to release earnings on Tuesday, and investors will closely monitor these reports to assess corporate performance in the current economic climate and its impact on the market.
- Iran Proposal Impact: President Trump discussed Iran's proposal to reopen the Strait of Hormuz if the U.S. lifts its blockade and ends the war, which could influence global oil prices and market sentiment amid ongoing uncertainty.
- Central Bank Meetings Outlook: This week, the U.S. Federal Reserve, European Central Bank, and Bank of England will hold pivotal meetings, with markets expecting them to maintain benchmark interest rates, while leaving the door open for potential hikes later this year, reflecting concerns over inflation and economic growth.
See More
Novartis Q1 Earnings Announcement Scheduled
- Earnings Release Date: Novartis is set to announce its Q1 earnings on April 28 before market open, with consensus EPS estimate at $2.07 and revenue expected at $13.48 billion, indicating significant market anticipation for the company's performance.
- Historical Performance Review: Over the past two years, Novartis has beaten EPS estimates 75% of the time and revenue estimates 63% of the time, showcasing a stable performance that bolsters investor confidence amid market scrutiny.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and two downward adjustments, reflecting a cautious market outlook on Novartis's future growth.
- Market Reaction Analysis: Despite facing 'historic' patent cliffs, analysts remain optimistic about Novartis's growth potential, suggesting that the company’s innovation and market strategies could lead to sustained growth opportunities.
See More
Novartis' Rhapsido Approved by EU for Chronic Spontaneous Urticaria
- Drug Approval: Novartis' Rhapsido (remibrutinib) has received approval from the European Commission for adult patients with chronic spontaneous urticaria (CSU) who have an inadequate response to H1-antihistamine treatment, marking a significant advancement in the company's dermatological portfolio.
- Market Potential: Chronic spontaneous urticaria affects approximately 40 million people globally, with nearly twice as many women as men, highlighting Rhapsido's substantial market potential in addressing unmet medical needs.
- Clinical Trial Success: In the Phase 3 REMIX 1 & 2 studies involving 925 patients who remained symptomatic on second-generation H1-antihistamines, Rhapsido demonstrated significant superiority over placebo in itch, hives, and weekly urticaria activity at Week 12, with a favorable safety profile.
- Future Development Directions: In addition to CSU, Rhapsido is also being developed for chronic inducible urticaria, food allergies, and hidradenitis suppurativa, further expanding its market applications.
See More
Novartis CEO Warns of U.S. Drug Pricing Policy Impact
- Pricing Policy Warning: Novartis CEO Vas Narasimhan warned that the U.S. drug pricing policy under President Trump poses a 'very difficult situation' for both drugmakers and patients, with the reality expected to set in within the next 18 months, potentially impacting stock prices and market confidence.
- Innovation Incentive Reform: He emphasized that Novartis is focused on urging European and Japanese governments to quickly change how they reward innovation; failure to do so could delay the entry of novel medicines into these markets, affecting patient access and potentially diminishing the company's competitiveness globally.
- Significant Long-term Implications: Narasimhan stated that the long-term implications of the drug pricing policy will be profound, potentially stifling innovation within the pharmaceutical industry and impacting the speed of new drug development and market entry, presenting strategic challenges for the company.
- Market Reaction Expectations: As the policy's effects become more apparent, Novartis may face pressure from investors and the market, particularly regarding its performance in drug innovation and market access, which could affect its future financial performance and shareholder confidence.
See More
BYD Faces EU Scrutiny Over Labor Abuse Allegations at Hungary Factory
- Labor Abuse Allegations: BYD has become the first Chinese company scrutinized by the European Parliament over allegations of labor abuses at its Hungary factory, highlighting increasing international regulatory attention on Chinese firms operating abroad.
- Working Conditions Investigation: A report by the New York-based watchdog China Labor Watch (CLW) claims that contractors at the factory kept thousands of employees working seven days a week with shifts exceeding 12 hours, indicating significant shortcomings in labor rights protections in the region.
- Employee Interviews Findings: CLW conducted interviews with 50 workers and visited the factory three times over the past months, revealing the harsh working conditions faced by employees, which could negatively impact BYD's brand image and reputation.
- Market Reaction Potential: This incident may raise investor concerns regarding BYD's operational risks in the European market, potentially affecting its competitive position in the global electric vehicle sector, especially as labor rights gain more attention.
See More
Novartis Q1 Core EPS Declines 15%, Missing Consensus
- Core EPS Decline: Novartis reported a 15% decline in Q1 core EPS, with a 13% drop in constant currency, reaching $1.99, which missed consensus estimates by $0.08, indicating pressure on the company's profitability.
- Net Sales Drop: The company's net sales fell 1% year-over-year and 5% in constant currency to $13.11 billion, missing consensus by $0.37 billion, highlighting challenges in market competition.
- Free Cash Flow Performance: Novartis generated $3.3 billion in free cash flow, which remains stable; however, the overall performance decline may impact future investments and shareholder returns.
- Full-Year Guidance Reaffirmed: The company reaffirmed its 2026 full-year guidance, expecting low single-digit growth in net sales and a low single-digit decline in core operating income, indicating ongoing efforts to seek growth amid patent expiration pressures.
See More
European Stocks Expected to Open Higher Amid Iran Proposal and Earnings Reports
- Market Opening Expectations: European stocks are expected to open slightly higher on Tuesday, with the U.K.'s FTSE 100, Germany's DAX, France's CAC 40, and Italy's FTSE MIB all showing gains, reflecting investor optimism ahead of upcoming earnings reports.
- Earnings Reports Focus: Companies such as Novartis, Airbus, BP, and Barclays are set to release earnings on Tuesday, and investors will closely monitor these reports to assess corporate performance in the current economic climate and its impact on the market.
- Iran Proposal Impact: President Trump discussed Iran's proposal to reopen the Strait of Hormuz if the U.S. lifts its blockade and ends the war, which could influence global oil prices and market sentiment amid ongoing uncertainty.
- Central Bank Meetings Outlook: This week, the U.S. Federal Reserve, European Central Bank, and Bank of England will hold pivotal meetings, with markets expecting them to maintain benchmark interest rates, while leaving the door open for potential hikes later this year, reflecting concerns over inflation and economic growth.
See More
